Department of Anesthesiology, LSU Health Shreveport, 1501 Kings Highway, Shreveport, LA, 71103, USA.
Candidate Class of 2019, LSU Health Shreveport, 1501 Kings Highway, Shreveport, LA, 71103, USA.
Best Pract Res Clin Anaesthesiol. 2018 Jun;32(2):165-178. doi: 10.1016/j.bpa.2018.06.008. Epub 2018 Jul 3.
There are several new anticoagulants on the market that will impact perioperative care, including the use of these anticoagulant drugs in the setting of regional anesthesia. The ideal pharmacological agent would prevent pathological thrombosis and allow for a normal response to vascular injury to limit bleeding. At present, all antithrombotic agents have increased bleeding risk as their main side effect. We describe the different categories of drugs, e.g., antiplatelet, anticoagulant, and thrombolytic, with particular emphasis on the new drugs that have been introduced into the market. These agents can be evaluated by a number of methods including low-, medium-, or high-risk procedures and guidelines and best practice standards that have been published regarding the amount of time to wait after stopping the medication and before performing a procedure, e.g., the American Society of Regional Anesthesia and Pain Medicine recommendations. The present investigation will also describe new reversal agents for anticoagulants and the implications of all these drugs for regional anesthesia.
市场上有几种新型抗凝剂将影响围手术期的护理,包括在区域麻醉的情况下使用这些抗凝药物。理想的药理学药物应该可以预防病理性血栓形成,并允许对血管损伤做出正常反应,以限制出血。目前,所有抗血栓药物的主要副作用都是增加出血风险。我们描述了不同类别的药物,例如抗血小板、抗凝和溶栓药物,并特别强调了已引入市场的新药。可以通过多种方法评估这些药物,例如低、中、高危手术和指南,以及已发布的最佳实践标准,这些标准涉及停止用药和进行手术之间等待的时间,例如美国区域麻醉和疼痛医学学会的建议。本研究还将描述抗凝剂的新型逆转剂以及所有这些药物对区域麻醉的影响。